Corporate ActionMay 19, 2026, 05:11 PM
Cellectar Biosciences Registers 51.2M Shares for Resale
AI Summary
Cellectar Biosciences filed an S-1 registration statement for the resale of up to 51,206,051 shares of common stock by selling stockholders. These shares originate from a private placement that closed on May 6, 2026, and include shares issued directly and those issuable upon the exercise of Pre-Funded Warrants and Series A, B, and C Warrants. While the company recently raised capital, the filing highlights that additional funding is required to continue operations, raising substantial doubt about its ability to continue as a going concern.
Key Highlights
- Cellectar Biosciences registered up to 51,206,051 shares of common stock for resale by selling stockholders.
- The shares include 2,116,887 from a private placement, 9,471,086 from Pre-Funded Warrants, and 39,618,078 from Series A, B, and C Warrants.
- The private placement closed on May 6, 2026, following agreements on May 4, 2026.
- Series A, B, and C Warrants have exercise prices of $2.65 or $2.88 per share.
- The company's cash balance of $13.2 million as of December 31, 2025, is expected to fund operations into Q2 2027.
- Cellectar Biosciences requires additional capital to continue operations, raising substantial doubt about its going concern ability.
- Ladenburg Thalmann & Co. Inc. received an 8.0% cash fee and warrants to purchase 792,362 shares as placement agent.
- Nantahala Capital Management, LLC will appoint Andrew Gu to the company's Board of Directors.
- The last reported sale price of common stock on May 18, 2026, was $3.14 per share.
Price Impact
More from CLRB